Novel Therapies for Familial Hypercholesterolemia

Area of Science:

• Cardiology
• Metabolic Disorders
• Pharmacology

Background:

• Familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH) are genetic lipid disorders requiring comprehensive management.
• Dietary and lifestyle modifications are foundational for both HeFH and HoFH patients.

Purpose of the Study:

• To outline current pharmacotherapy strategies for adult HeFH and HoFH, emphasizing guideline-driven approaches.
• To discuss the role of various drug classes and apheresis in managing severe hypercholesterolemia.

Main Methods:

• Review of American Heart Association (AHA) and European Atherosclerosis Society (EAS) guidelines for hypercholesterolemia management.
• Description of stepwise pharmacotherapy including statins, ezetimibe, PCSK9 inhibitors, bile acid-binding resins, lomitapide, and mipomersen.
• Consideration of LDL-C apheresis and liver transplantation for refractory HoFH cases.

Main Results:

• The AHA algorithm recommends high-potency statins initially for HeFH, with escalating therapy including ezetimibe and PCSK9 inhibitors.
• LDL-C apheresis is indicated for severe hypercholesterolemia (e.g., LDL-C >300 mg/dL or >160 mg/dL with CAD).
• HoFH management requires specialized centers, early consideration of apheresis from age 5, and often combination pharmacotherapy.

Conclusions:

• Pharmacotherapy for HeFH and HoFH is guided by established algorithms, progressing from statins to combination therapies and advanced interventions.
• Aggressive LDL-C lowering is crucial, with apheresis and other advanced treatments reserved for severe or refractory cases.
• Multidisciplinary care at experienced centers is vital for optimal management of HoFH patients.